Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF20513 Extension Study in Alzheimer's Disease
NCT03668405Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of Lu AF20513 in Alzheimer's disease (AD), sponsored by Lundbeck. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Aβ-specific antibody titre in plasma. Started Jun 2018; status: terminated.
02
Drugs
Lu AF20513
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03668405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668405.